AARD - Aardvark Therapeutics Inc
NYSE * Health Care * Biotechnology
$15.29
$-0.09 (-0.55%)
About Aardvark Therapeutics Inc
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen, which is in the Phase 3 clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in the Phase 2 clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from the treatment of craniopharyngioma, including surgery or radiation. The company is also developing ARD-201, which is in the Phase 1 clinical trial for the treatment of obesity. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
AARD Key Statistics
Market Cap
$334.66M
P/B Ratio
2.73
EPS
$-2.53
Employees
33
How AARD Compares to Peers
P/E Rank
N/A
of 5
Margin Rank
N/A
of 5
Growth Rank
N/A
of 5
Size Rank
#6
of 6
Aardvark Therapeutics Inc Company Information
- Headquarters
- California; U.S.A
- Website
- www.aardvarktherapeutics.com
- Sector
- Health Care
- Industry
- Biotechnology